Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer

Table 3 Univariate analysis of potential factors associated with overall survival in patients with locally advanced NSCLC

Variables	Case	Overall survival	p*
Variables	Case	Median (months)	p*
Age			0.691
< 60	164	21
≥ 60	168	17
Gender			0.492
Male	206	18
Female	126	19
Smoking status			0.154
Never smoker	141	21
Current or ex-smoker	191	16
ECOG PS			< 0.001
0–1	304	21
2	28	12
Histological subtype			0.654
Adenocarcinoma	154	18
Squamous	161	21
Other histology	17	14
T stage			0.002
T1–T2	181	22
T3–T4	151	14
N stage			0.028
Negative	24	42
Positive	308	17
Clinical stage			0.034
III A	197	21
III B	135	15
Chemotherapy cycles			0.741
< 4	72	16
≥ 4	260	19
SII			< 0.001
< 660	183	30
≥ 660	149	10
NLR			< 0.001
< 3.57	195	28
≥ 3.57	137	10
PLR			< 0.001
< 147	179	27
≥ 147	153	11
PNI			< 0.001
≥ 52.95	94	36
< 52.95	238	15

CR complete response, PR partial response, PD progressive disease, SD stable disease, SII systemic immune-inflammation index, NLR neutrophil/lymphocyte ratio, PLR platelet/lymphocyte ratio, PNI prognostic nutritional index
* p log-rank test

ISSN: 1479-5876